Dermorphin is a natural heptapeptide originally isolated from the skin of South American phyllomedusid frogs, characterized by its extraordinary potency and selectivity for mu-opioid receptors. Synthesized for strict laboratory research use, this compound is a vital pharmacological probe for investigating receptor kinetics, structural modifications, and central nociceptive processing in vitro and in vivo models.
Dermorphin is a natural heptapeptide originally isolated from the skin of South American phyllomedusid frogs, characterized by its extraordinary potency and selectivity for mu-opioid receptors. Synthesized for strict laboratory research use, this compound is a vital pharmacological probe for investigating receptor kinetics, structural modifications, and central nociceptive processing in vitro and in vivo models.
A dermorphin laboratory peptide is a high-purity, synthetic heptapeptide (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) engineered exclusively for in vitro and preclinical research applications. Renowned for its exceptional binding affinity and intrinsic activity at mu-opioid receptors, dermorphin serves as a benchmark standard in biochemical assays evaluating ligand-receptor interactions, signaling cascades, and peptide stability.
Originally discovered in the skin secretions of *Phyllomedusa sauvagei*, dermorphin stands out among natural peptides due to the presence of a D-alanine residue at position 2. This post-translational enzymatic modification (or intentional stereochemical inclusion during solid-phase synthesis) confers remarkable enzymatic resistance against metabolic degradation by aminopeptidases. As a research tool, the dermorphin laboratory peptide enables precise mapping of central nervous system pathways, structural biology assays, and Comparative receptor binding studies across diverse laboratory environments.
The primary sequence of dermorphin—Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2—contains a distinctive stereochemical feature that distinguishes it from endogenous mammalian opioid peptides such as enkephalins and endorphins. Incorporating an L-tyrosine at the N-terminus followed immediately by a D-alanine residue creates a conformational restriction that dramatically increases receptor selectivity while reducing enzymatic cleavage by serum proteases.
In structural biology assays, the presence of D-alanine at position 2 stabilizes the active beta-turn conformation required for optimal alignment within the binding pocket of the mu-opioid receptor. Nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography demonstrate that this exact spatial orientation minimizes sterically hindered non-productive binding modes. Researchers investigating novel peptidomimetic designs frequently utilize dermorphin as a structural scaffold to understand how D-amino acid substitution alters thermodynamic stability and bioavailability in experimental media.
Preclinical binding assays indicate that dermorphin demonstrates an exceptionally high affinity for the mu-opioid receptor (MOR), with inhibition constants ($K_i$) typically operating in the sub-nanomolar range. Comparative binding experiments show that dermorphin possesses orders of magnitude higher selectivity for MOR over delta-opioid receptors (DOR) and kappa-opioid receptors (KOR). This remarkable specificity makes it an essential control compound when characterizing unmapped receptors or novel synthetic ligands within the all-peptides catalog.
Upon ligand binding, dermorphin stimulates G-protein coupling, leading to the inhibition of adenylyl cyclase activity, decreased intracellular cyclic AMP (cAMP) accumulation, and modulation of voltage-gated calcium and inwardly rectifying potassium channels. In vitro cell culture models expressing recombinant human or rodent opioid receptors utilize dermorphin to measure G-protein recruitment versus beta-arrestin signaling pathways, aiding researchers in mapping biased agonism dynamics in central signaling cascades.
In vivo rodent models evaluating central pain transmission demonstrate that central administration (e.g., intracerebroventricular or intrathecal) of dermorphin produces profound analgesia at significantly lower molar concentrations than classical alkaloid or endogenous peptide agonists. Preclinical literature attributes this pronounced potency to a combination of high intrinsic receptor efficacy and prolonged resistance to central peptidase clearance.
Beyond antinociceptive models, laboratory investigations utilize dermorphin to study central respiratory control networks, gastrointestinal transit inhibition, and neuroendocrine hormone secretion pathways in laboratory animals. These studies provide crucial data regarding the differential distribution of opioid receptor subtypes in central versus peripheral nervous system tissues, helping researchers isolate specific physiological responses driven exclusively by mu-opioid activation.
When designing comparative binding assays or exploring opioid receptor subtype dynamics, researchers often evaluate dermorphin alongside structural and functional analogs within the same class. While dermorphin functions as a potent, highly selective mu-opioid agonist, compounds such as deltorphin II exhibit extreme selectivity for the delta-opioid receptor despite sharing a similar amphibian-derived peptide lineage and D-amino acid motif.
Similarly, research evaluating synthetic bivalent or multifunctional opioid constructs often benchmarks performance against biphalin, a dimeric peptide with balanced mu/delta affinity, or dalargin, a leu-enkephalin analog modified for peripheral stability. Comparing dermorphin against these distinct ligands in parallel binding protocols allows research teams to map subtle variations in receptor activation thresholds, internalizing kinetics, and downstream intracellular signaling pathways within complex neural tissue cultures.
To ensure reliable, reproducible data across preclinical assays, research peptides must adhere to stringent purity and analytical specifications. PX1 Research subjects every production lot of dermorphin laboratory peptide to rigorous quality control testing in ISO 17025 accredited analytical facilities.
Key analytical testing parameters include Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity exceeding 98.0%, and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular weight and structural sequence integrity. Additionally, quantitative Limulus Amebocyte Lysate (LAL) testing is performed to ensure endotoxin levels remain below strictly controlled limits (<0.01 EU/μg), preventing confounding inflammatory responses in sensitive cell culture or tissue bath experiments.
Proper handling and storage are critical to maintaining the chemical stability and biological activity of lyophilized dermorphin. Upon arrival, the sealed vial should be stored in a temperature-controlled freezer at -20°C or -80°C, protected from light and moisture exposure. Prior to opening, vials should be allowed to equilibrate to room temperature to prevent condensation from forming on the lyophilized cake.
Reconstitution should be conducted under sterile laminar flow conditions using sterile, deionized laboratory-grade water or suitable aqueous buffers such as phosphate-buffered saline (PBS, pH 7.4). For long-term storage of reconstituted stock solutions, aliquoting into single-use polypropylene microtubes is recommended to avoid destructive freeze-thaw cycles. Reconstituted aliquots stored at -80°C maintain chemical stability for extended research timelines when documented according to standard laboratory operation procedures.
Acquiring analytical-grade compounds requires transparent supply chains and complete lot traceability. PX1 Research operates fully compliant domestic manufacturing and distribution workflows, shipping directly from specialized facilities in California and Arizona with same-day dispatch for orders finalized Monday through Friday.
Principal investigators and procurement specialists can access downloadable, lot-specific Certificates of Analysis (COA) directly through our comprehensive research hub. Institutional buyers requiring bulk quantities or recurring delivery schedules for ongoing study protocols are encouraged to establish a dedicated account via our wholesale portal, ensuring standardized batch quality and dedicated scientific support.
What is the primary target receptor of dermorphin in laboratory research?
Dermorphin is a highly selective agonist for the mu-opioid receptor (MOR), exhibiting nanomolar affinity and minimal binding affinity for delta (DOR) or kappa (KOR) opioid receptor subtypes.
Why is D-alanine present in the dermorphin peptide sequence?
The incorporation of D-alanine at position 2 confers structural resistance against degradation by aminopeptidase enzymes, significantly enhancing the peptide's stability in biological media during laboratory experiments.
How is the purity of PX1 Research dermorphin verified?
Every lot of dermorphin undergoes third-party verification using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm >98% purity, combined with Mass Spectrometry (ESI-MS) for sequence identification.
What solvent is recommended for reconstituting lyophilized dermorphin?
Lyophilized dermorphin readily dissolves in sterile laboratory-grade water or sterile phosphate-buffered saline (PBS, pH 7.4). Solvents should be selected based on the specific requirements of the downstream in vitro or analytical assay.
What are the recommended storage conditions for long-term stability?
Lyophilized dermorphin should be stored at -20°C or -80°C. Reconstituted stock solutions should be divided into single-use aliquots and maintained at -80°C to minimize degradation from repeated freeze-thaw cycles.
Does PX1 Research perform endotoxin testing on dermorphin?
Yes, all production batches undergo Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels meet strict laboratory standards (<0.01 EU/μg), preventing non-specific cellular activation in experimental models.
How does dermorphin differ functionally from deltorphin?
While both are amphibian-derived peptides containing D-amino acids, dermorphin is highly selective for the mu-opioid receptor, whereas deltorphin displays exceptional selectivity for the delta-opioid receptor.
Can dermorphin be purchased for clinical or veterinary therapeutic use?
No. Dermorphin supplied by PX1 Research is strictly designated for laboratory research use only (RUO) in in vitro assays and preclinical animal models. It is not for human or veterinary administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.